TY - JOUR AU - Heinz, Amadeus T AU - Ebinger, Martin AU - Schönstein, Anton AU - Fuchs, Jörg AU - Timmermann, Beate AU - Seitz, Guido AU - Vokuhl, Christian AU - Münter, Marc W AU - Pajtler, Kristian AU - Stegmaier, Sabine AU - von Kalle, Thekla AU - Kratz, Christian P AU - Rößler, Jochen AU - Ljungman, Gustaf AU - Klingebiel, Thomas AU - Koscielniak, Ewa AU - Sparber-Sauer, Monika TI - Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR). JO - Pediatric blood & cancer VL - 70 IS - 7 SN - 1545-5009 CY - New York, NY PB - Wiley M1 - DKFZ-2023-00771 SP - e30363 PY - 2023 N1 - 2023 Jul;70(7):e30363 AB - Outcome of relapsed disease of localized rhabdomyosarcoma remains poor. An individual treatment approach considering the initial systemic treatment and risk group was included in the Cooperative Weichteilsarkom Studiengruppe (CWS) Guidance.Second-line chemotherapy (sCHT) ACCTTIVE based on anthracyclines (adriamycin, carboplatin, cyclophosphamide, topotecan, vincristine, etoposide) was recommended for patients with initial low- (LR), standard- (SR), and high-risk (HR) group after initial treatment without anthracyclines. TECC (topotecan, etoposide, carboplatin, cyclophosphamide) was recommended after initial anthracycline-based regimen in the very high-risk (VHR) group. Data of patients with relapse (n = 68) registered in the European Soft Tissue Sarcoma Registry SoTiSaR (2009-2018) were retrospectively analyzed.Patients of initial LR (n = 2), SR (n = 16), HR (n = 41), and VHR (n = 9) group relapsed. sCHT consisted of ACCTTIVE (n = 36), TECC (n = 12), or other (n = 15). Resection was performed in 40/68 (59 KW - Soft Tissue Sarcoma Registry (SoTiSaR) (Other) KW - localized disease (Other) KW - relapsed disease (Other) KW - rhabdomyosarcoma (Other) KW - second-line chemotherapy (Other) LB - PUB:(DE-HGF)16 C6 - pmid:37066598 DO - DOI:10.1002/pbc.30363 UR - https://inrepo02.dkfz.de/record/275451 ER -